A carregar...
Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinoma
Everolimus is an oral inhibitor of mammalian target of rapamycin (mTOR-I) and is currently approved for the treatment of metastatic renal cell carcinoma (mRCC) after failure of first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor (TKI). In this narrative review, we aim to...
Na minha lista:
| Publicado no: | Ther Adv Urol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4549702/ https://ncbi.nlm.nih.gov/pubmed/26425143 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756287215591764 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|